Supernus Pharmaceuticals, Inc. Expected to Earn FY2025 Earnings of $2.83 Per Share (NASDAQ:SUPN)


Share on StockTwits

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Analysts at Piper Sandler raised their FY2025 earnings per share (EPS) estimates for shares of Supernus Pharmaceuticals in a research note issued to investors on Monday, April 5th. Piper Sandler analyst D. Amsellem now anticipates that the specialty pharmaceutical company will post earnings of $2.83 per share for the year, up from their prior forecast of $2.80. Piper Sandler has a “Overweight” rating and a $35.00 price target on the stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, February 25th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.57. Supernus Pharmaceuticals had a return on equity of 20.02% and a net margin of 27.09%. The firm had revenue of $143.56 million during the quarter, compared to the consensus estimate of $145.52 million.

Other analysts also recently issued reports about the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, March 31st. TheStreet raised shares of Supernus Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Tuesday, January 5th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $27.75.

Shares of Supernus Pharmaceuticals stock opened at $28.25 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.70 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average price of $26.96 and a two-hundred day moving average price of $24.63. Supernus Pharmaceuticals has a 1-year low of $17.20 and a 1-year high of $31.99. The company has a market cap of $1.50 billion, a P/E ratio of 11.72 and a beta of 1.38.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vantage Consulting Group Inc bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $26,000. Penserra Capital Management LLC lifted its position in Supernus Pharmaceuticals by 167.7% in the 4th quarter. Penserra Capital Management LLC now owns 1,210 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 758 shares in the last quarter. Perigon Wealth Management LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $32,000. Aequim Alternative Investments LP lifted its position in Supernus Pharmaceuticals by 2,701.7% in the 4th quarter. Aequim Alternative Investments LP now owns 1,300,000 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 1,253,600 shares in the last quarter. Finally, Veriti Management LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter valued at about $171,000. 96.11% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Recommended Story: Cost of Debt

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.